The Global Drug Delivery Technologies market will reach $259.1bn in 2020 predicts new visiongain report

04 September 2018
Pharma

A new report by visiongain predicts that the Global Drug Delivery Technologies market will reach $259.1bn in 2020. This forecast and others appear in Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes—published in July 2016. Visiongain is a business information provider based in London, UK.

Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report examines the current and future trends in the growing drug delivery technologies market. As the generic drug industry continues to see rapid growth, big pharma companies will continue to strive for extensions on their product life-cycles. Drug delivery technologies are of high demand not only because of the deep interest shown by pharma companies in recent years but also the dire need to improve patient compliance. Yemi Adebayo, a Pharmaceutical and Medical Devices Analyst at visiongain comments:
“Drug delivery technologies provide ample opportunities for both biopharmaceutical companies that offer services providing new technologies and pharmaceutical companies attempting to extend the product lifecycle of their product. The drug delivery technologies market will see fast growth over the next ten years. The oral drug delivery market remains the most dominant submarket, which is largely due to the convenience of taking drugs orally. However, with increasing numbers of biologic medicines we expect to see the injectable drug delivery tech market grow rapidly over the forecast period. The problem with using the parenteral route for drug delivery is the inconvenience it brings to patients. As such, novel ways of administering biologics will be sought. This, together with the growing burden of an ageing population and rise in chronic diseases in most developed countries will continue to cause demand for new ways of delivering drugs to their intended target.”
In this report, we examine in detail the drug delivery technologies market, and provide analyses and forecasts for regional and national markets. Historical revenues have also been added to strengthen our analysis to demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.

Visiongain’s report provides revenue forecasts to 2026 for the global biologics market, the global vaccines market and the global drug delivery technologies market and the leading regional and national drug delivery technologies markets. The report discusses selected leading companies in the market. These companies include Alkermes, 3M, Skyepharma, Becton Dickinson and Company (BD), Antares Pharma, pSivida, Applied Pharma Research (APR), Ethypharm, Glycologic and NanoPass Technologies

Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 61
About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional that needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever